🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

For #HeadanNeckCancerAwarenessMonth, we spoke with Akina Tamaki, MD of @FoxChaseCancerCenter, to discuss developments in the #headandneckcancer landscape, including improved treatment strategies and multidisciplinary approaches. #hncsm Read the Q&A: hubs.li/Q03h-z2Z0

Join us for the 13th Annual Giants of Cancer Care® Awards Ceremony on May 29, where oncology’s luminaries are honored for their lasting contributions. RSVP now: hubs.li/Q03h-64m0

Treatment with a novel, optimized, hinge dual CD19/CD20–directed CAR T-cell therapy was safe and elicited high response rates, particularly when administered after ASCT, in patients with relapsed/refractory B-cell #lymphoma. The EBMT #EBMT2025 hubs.ly/Q03h_GxD0

The rates of Epstein-Barr virus reactivation were 2.3% and 25.4% in the Orca-T and CD34 arms, respectively, in patients with select hematologic malignancies. The EBMT #EBMT2025 #Hematology hubs.ly/Q03h_Ffh0

At the data cutoff, data from the phase 1 study of ASP3082 showed that patients with #NSCLC who received the agent at 300 to 600 mg experienced an ORR of 23.1% and a DCR of 84.6%. Benjamin Herzberg Herbert Irving Comprehensive Cancer Center #LCSM Read more: hubs.li/Q03hf3jL0

Patients with FRα+, platinum-resistant #OvarianCancer, treated with mirvetuximab soravtansine achieved a median OS of 16.85 months vs 13.34 months in those treated with investigator’s choice of chemotherapy. UZ Leuven #gyncsm hubs.li/Q03hf72J0

Following the OncLive National Fellows Forum® at SABCS, Drs Tess O’Meara and Kelsey H. Natsuhara discussed profiling tumor-associated immune cells on #BreastCancer and the effect of telehealth on patient access.Tess O'Meara, MD, MHS Kelsey Natsuhara hubs.li/Q03hfHMX0

The recent #FDAapproval of cabozantinib for select patients with well-differentiated pNETs and epNETs was based on results from the phase 3 CABINET trial. U.S. FDA hubs.li/Q03hfP1j0

Orthopedic Oncology Experts Shape Global Consensus on Chondrosarcoma Management R. Lor Randall UC Davis Department of Orthopaedic Surgery @UCDCancer UC Davis Health #chondrosarcoma onclive.com/view/orthopedi…

Akina Tamaki, MD, of Fox Chase Cancer Center highlights treatment considerations, the therapeutic arsenal, and surgical advancements in head and neck cancer. Read the full article here: hubs.li/Q03hYqrQ0

It's time for the #OncFive 5⃣, your quick roundup of the top 5 stories from the world of #oncology. Check out what made the list 🔗: onclive.com/view/the-oncfi…

Efficacy-evaluable patients with platinum-resistant or -refractory #OvarianCancer achieved a median OS of 190 days and a median PFS of 98 days following treatment of ILT-123 plus pembrolizumab. #gyncsm hubs.li/Q03hgD3q0

Stop scrolling! 🛑✋ Catch up on the top 5 #Oncology articles from last week, including 3 #FDA approvals and news related to #NSCLC and #SCLC. #OncFive #OncLive Find them all here: hubs.li/Q03hgQ7z0

It's important to understand the AEs associated with MEK inhibitors to treat neurofibromatosis type 1–associated #PlexiformNeurofibromas to ensure patients derive the greatest benefit. UMN Medical School hubs.ly/Q03hHx3z0

At a data cutoff date of August 23, 2024, adagrasib/pembrolizumab elicited an ORR of 59% in patients KRAS G12C–mutated #NSCLC, which included: - CRs (57%) - SD (22%) - PD (4%) #ELCC25 Marina Garassino The University of Chicago Read for more data: hubs.li/Q03hHqJj0

At a data cutoff date of January 14, 2025, fulzerasib/cetuximab elicited an ORR of 80.0% in evaluable patients with KRAS C12C–mutated advanced #NSCLC. #ELCC25 #LCSM hubs.li/Q03hHNR00

.Dr. Maurie Markman highlights the constant timeliness of ethical considerations in cancer care, particularly with the discussion of placebo use in phase 3 trials. #Ethics #CancerCare Read the article here: hubs.li/Q03hH-g30

The positive opinion from the EU Medicines Agency' CHMP was supported by data from the phase 3 CheckMate 77T trial, which showed that certain patients treated with perioperative nivolumab plus chemotherapy experienced a median EFS that was not reached. #lcsm hubs.li/Q03hJlFW0

Hear Marc R. Matrana, MD, of Ochsner Health share his approach to navigating treatment selection when initiating therapy for patients with RCC. Watch the full video here: hubs.li/Q03j0h5d0

The EU Medicines Agency' CHMP recommendation of approval for the subcutaneous formulation of nivolumab co-formulated with recombinant human hyaluronidase in #SolidTumors was supported by data from the phase 3 CheckMate 67T trial. hubs.li/Q03hK5V80